Thoracic endovascular aortic repair (TEVAR) for thoracic aortic disease constitutes a paradigm shift in the treatment strategy of aortic dissection, as well as thoracic aortic aneurysms. Conventionally, most patients with Stanford type B acute aortic dissection are treated using conservative medical treatment during the acute phase. However, in patients with complicated type B aortic dissection who present with life-threatening complications, TEVAR has been introduced as a novel and less-invasive alternative and has shown better early results than those observed with conventional therapy. Recently, TEVAR was reported to be effective in not only promoting thrombosis of the false lumen but also in preventing aortic enlargement observed at long-term follow-up. TEVAR has been established as first-line therapy for complicated type B aortic dissection. In contrast, a considerable number of patients who received acute phase medical treatment required surgical intervention for chronic dissecting aortic aneurysms. With the increasing popularity of TEVAR for the treatment of complicated type B aortic dissection, prophylactic and pre-emptive TEVAR has been considered in patients with uncomplicated type B aortic dissection. However, supportive evidence for this strategy is limited, and reassessment is mandatory because it is continuously evolving. Although acute type A aortic dissection is a life-threatening condition, the results of open surgery continue to improve in the modern surgical era. Open surgical treatment is well established and recognized as a gold standard even in the endovascular era. Presently, the application of TEVAR for ascending aortic dissection has undergone a change, and TEVAR is considered a viable rescue option for patients with type A aortic dissection who are not eligible for open surgical repair. However, TEVAR for the descending aorta is well-established treatment for retrograde type A dissection. Several conceptual and technical issues remain unresolved, and technological advances would lead to the development of innovative disease-specific devices and solutions in the future for endovascular treatment of acute aortic dissection. (This is a translation of Jpn J Vasc Surg 2018; 27: 337-345.) 
Introduction
Thoracic endovascular aortic repair (TEVAR) has achieved a major paradigm shift in the treatment of both atherosclerotic thoracic aortic aneurysm and chronic aortic dissection. Traditionally, resting antihypertensive treatment has been the standard treatment for acute type B aortic dissection, but aggressive acute phase surgical intervention by TEVAR has now become widespread for complicated type B aortic dissection. In addition, it is now covered by medical insurance in Japan, and quite favorable results have been reported. In recent years, the indication has expanded to include uncomplicated type B aortic dissection with the intention of preventing future aortic events. In addition to discussing the current status of TEVAR for acute type B aortic dissection, this paper mentions the possibility of its use in the treatment for acute type A aortic dissection.
TEVAR for Acute Type B Aortic Dissection
Prior to the popularization of TEVAR for acute type B aortic dissection in Japan, the INSTEAD-XL study was published in 2013 1) and the European Society of Cardiology (ESC) Guidelines were revised in 2014 2) ( Table 1) . TEVAR for complicated type B aortic dissection, such as organ ischemia, was listed as class IIa in the 2001 ESC guidelines 3) but was changed to class I in the revised version. Furthermore, TEVAR was also listed as class IIa for the first time for uncomplicated type B aortic dissection. Since then, the concept and selection of preventive TEVAR has been added as a surgical option in the treatment for TEVAR for Acute Aortic Dissection acute type B aortic dissection.
TEVAR procedure for acute type B aortic dissection
The principle of surgical treatment in acute aortic dissection is aortic resection including the intimal tear (entry) and closure of the false lumen by reapproximating the dissected aortic wall. The concept is the same in TEVAR, with the aim of reducing the pressure inside the false lumen and thrombosis by covering the intimal tear with a stent graft (Fig. 1) . For entry closure in the vicinity of the left subclavian artery, covering and debranching of the origin of the left subclavian artery are considered to be appropriate for securing an adequate landing zone on the proximal side. It is important to place the stent graft after ensuring that the true lumen has been visualized by intravascular ultrasound (Fig. 1) . It has also been suggested with regard to the optimal size of the stent graft that a device with the same diameter as the true lumen diameter, or with a 10% increase beyond this diameter, should be selected; however, because there is a high degree of bias in the measurement of the true lumen diameter, the difference in radial force between each device, etc., no consensus on this topic has been reached. Recently, in addition to entry closure by a covered stent, provisional extension to induce complete attachment (the PETTICOAT technique) [4] [5] [6] has been performed by the bare stent placement to facilitate true lumen expansion (Fig. 2) . The residual blood flow into the false lumen via the peripheral reentry after TEVAR is a major factor related to the enlargement of a dissecting aortic aneurysm in the chronic phase and remains an important problem.
Complicated type B
Because many patients who underwent emergency surgery for acute complicated type B aortic dissection prior to the introduction of TEVAR had complications due to rupture and severe organ malperfusion, treatment results were extremely poor. Aortic replacement surgery via lateral thoracotomy, extra-anatomical bypass surgery, fenestration of intimal flap via laparotomy or using a catheter, etc., were performed in response to various pathological conditions, but the in-hospital mortality rates regarding operative treatment for type B aortic dissection in the acute phase were very high (32.1%). 7) Fortunately, the recent introduction of TEVAR has greatly contributed to the improvement of the treatment outcomes of this patient group. Although patient background issues such as their preoperative conditions and the timing of surgical intervention were not always the same, the short-term outcome of TEVAR for acute complicated type B aortic dissection has been favorable, as reported in the literature. [4] [5] [6] According to Szeto et al., 8 ) the 30-day postoperative mortality rate of 35 patients who underwent TEVAR for acute complicated type B aortic dissection was only 2.8% and the 1-year survival rate was 93.4%. Hanna et al. 9) also reported that no cases of mortality were noted in 30 days following TEVAR, and postoperative results were favorable; however, in the chronic phase, >25% of the patients required additional treatment. 9) The series of Bavaria et al. 10) reported that although the mortality rates at 30 days and 1 year postoperatively were favorable (8% and 15%, respectively), the incidence of paraplegia was 6%, and some sort of aorta-related complications occurred within 1 year in approximately 50% of the patients. 10) In the current Guidelines for Diagnosis and Treatment of Aortic Aneurysm and Aortic Dissection of the Japanese Circulation Society (Table 2) , TEVAR for acute complicated type B aortic dissection is listed as class I. 11) Recent findings have reported that TEVAR is effective for aortic remodeling to promote the thrombosis of the false lumen in the long term and to prevent the enlargement of the thoracic aorta. 12) In addition, TEVAR for acute complicated type B aortic dissection has been established as the first choice for acute treatment. 13, 14) Although attention has been paid to the favorable short-term results of TEVAR, how to prevent the aortic events in the long term remains an important issue.
Uncomplicated type B
The purpose of initial treatment of acute uncomplicated type B aortic dissection is the prevention of aortic events in the acute phase in many institutions at present. However, after undergoing conservative treatment in the acute phase, numerous patients have presented with the formation of a dissecting aortic aneurysm during follow-up, and these require surgical treatment in the chronic phase. TEVAR for acute uncomplicated type B aortic dissection is performed from the viewpoint of preventing aortic events such as aneurysmal formation and rupture during the chronic phase. In the Japanese guidelines, the use of TEVAR for the purpose of preventing the chronic aneurysmal formation in acute uncomplicated type B aortic dissection is listed as class IIb. However, the accumulation of evidence including the prognosis in the long term is insufficient, and at present, TEVAR has not yet been established as the primary treatment method in Japan, where it is not It is a prerequisite that the above procedures are conducted in hospitals skilled in endovascular treatment.
Adopted from Reference 11.
TEVAR for Acute Aortic Dissection covered by medical insurance, like Western countries. 11, 15) 
Results of TEVAR for acute type B aortic dissection
According to the International Registry of Acute Aortic Dissection, 14) the 3-year survival rate of patients who underwent conservative treatment for acute type B aortic dissection is 75%-80%. 14) In Japanese reports, the overall survival rates of conservative treatment for type B dissection 5 years after onset in cases of patent false lumen and thrombosed false lumen were 64%-79% and 74%-97%, respectively. [16] [17] [18] All these reports concern commercially available TEVAR devices, but there is no significant change in mortality and morbidity rates with conservative treatment for type B aortic dissection after the introduction of TEVAR. The aortic event-free survival rate in the 10 years after the onset of type B aortic dissection among our cases was 77% for the group in which aortic enlargement was observed in the chronic phase and 79% in the group in which it was not observed. 19) The short-term survival rate of patients with acute type B aortic dissection in which strict resting blood pressure management is performed is generally favorable, 20) but there has been a significantly large groups of patients requiring surgical intervention in the chronic phase, and it was indicated that their survival rate was poor compared with the group that underwent TEVAR in the acute phase. [21] [22] [23] According to one study, 9) the surgical results of TEVAR for acute complicated type B aortic dissection were favorable, with no cases of in-hospital mortality being noted, and the incidence of cerebrospinal disorder was low (2%). However, as of the mean observation period of 34 months, the fact that 26% of cases required re-intervention for various reasons is clearly a problem. Still, according to the database of the ADSORB trial, which is a prospective randomized study of acute type B aortic dissection, 24) mortality within 30 days was not noted in either the conservative treatment group or the TEVAR group for acute uncomplicated type B aortic dissection, and short-term outcomes were favorable. However, although observation after 1 year revealed true lumen expansion and false lumen constriction in the TEVAR group, the true lumen diameter did not change in the conservative treatment group; instead, the data showed that the false lumen had expanded.
Complications following TEVAR for aortic dissection include stent graft-induced new entry (SINE) 25, 26) (Fig. 3) , retrograde type A aortic dissection (RTAD) 27, 28) (Fig. 4) , and enlargement of the residual false lumen, 29) all of which can cause severe or lethal pathological conditions. It has been reported that the onset of SINE is more frequent in TEVAR in the chronic phase than in the acute phase, 26) and stent graft oversizing has been reported as a common risk factor for both SINE and RTAD, 26) but there is no definitive consensus for the procedure as a preventive measure for postoperative complications related to stent grafting. If a surgical procedure-related problem occurs after a prophylactic TEVAR for acute uncomplicated type B aortic dissection, invasive treatment that was not originally necessary to be performed more than once may become necessary depending on the situation.
Problems noted regarding current acute type B aortic dissection include (i) characteristics of cases of future aneurysm formation and (ii) the optimal timing of TEVAR. In particular, there are many reports on what kinds of cases cause enlargement of aneurysm size and formation of dissecting aortic aneurysm, and it turns out to be largely related to the determination of TEVAR indication criteria for acute uncomplicated type B aortic dissection. It is necessary to carefully plan TEVAR for acute uncomplicated type B aortic dissection, taking into consideration that it is a prophylactic treatment. Therefore, for these patients, it is important to precisely identify and intervene in acute phase cases only when treatment is actually necessary, that is, cases in which the risk of onset of aortic events in the chronic phase is significant. Risk factors for poor prognosis of acute type B aortic dissection, that is, the onset of aortic events include being male, 30) partial thrombosis of the false lumen, 31) having an aortic diameter exceeding 40 mm, 19, 32, 33) early aortic diameter expansion, 34) onset at young age, 33, 35) false lumen located on the small curvature side, 30) and the diameter of the intimal tear exceeding 10 mm. 29, 36) Examinations from various viewpoints have been reported in cases wherein branches originated in the false lumen and the aortic diameter tended to expand, 37) and it was found that the greater the number of intercostal arteries, the higher the tendency for the aneurysmal change. 38) Favorable results have also been reported using the PETTICOAT technique to expand the true lumen. Regarding the treatment results of TEVAR combined with PET-TICOAT together for type B aortic dissection with acute to subacute complications, the 30-day mortality rate was 0%-5.0%, and false lumen regression was noted in 31%-80% of patients. However, there was a difference between institutions during the 1-year observation period. [4] [5] [6] Here, we present a case study using TEVAR with the PET-TICOAT technique for acute complicated type B aortic dissection (Figs. 5 and 6 ). Computed tomography (CT) performed 1 year after TEVAR revealed favorable true lumen expansion and disappearance of the false lumen.
Endovascular stent graft placement for acute type B aortic dissection is currently a worldwide topic in aortic surgery, and it is a field that is constantly debated at academic conferences. At present, there are many choices for the optimal timing of TEVAR intervention, as well as for various novel surgical procedures and techniques. It is essential to perform appropriate treatment with a view toward the long-term prognosis of patients rather than with a focus on novel procedures.
TEVAR for Acute Type A Aortic Dissection
Despite disease severity, the results of open surgery for acute type A aortic dissection are relatively favorable, and in the 2014 annual report of the Japanese Association for Thoracic Surgery, the surgical mortality rate in Japan was 10.6%. 39) With this background, the standard of treatment for acute type A aortic dissection in Japan as well as worldwide is open surgery. However, due to problems such as general status and complications, the mortality rate of patients not indicated for open surgery is very high The PETTICOAT technique, which consisted of stent graft coverage of the primary entry followed by bare metal stent placement to the downstream aorta. CT image soon after TEVAR showed the true lumen increased dramatically and thrombosis of the false lumen was induced. C: CT image 1 year after TEVAR showed complete remodeling of the descending aorta with complete disappearance of the false lumen. CT: computed tomography; PETTICOAT: provisional extension to induce complete attachment; TEVAR: thoracic endovascular aortic repair (approximately 60%), 40) ( Table 2) , and there are a few reports of entry closure by TEVAR of the descending aorta in clinical practice. 42, 43) Here we present a case in which TEVAR was performed on the descending aorta for retrograde acute type A aortic dissection (Fig. 7) . As the thrombosed false lumen of the ascending aorta expanded, an ulcer-like projection of the descending aorta was noted on CT; we therefore attempted TEVAR for the entry closure of the descending aorta. The false lumen of the ascending aorta completely disappeared 1 month after TEVAR.
TEVAR procedure for acute type A aortic dissection
The surgical procedure for TEVAR of the descending aorta for retrograde acute type A aortic dissection is almost the same as that for acute type B aortic dissection. In contrast, TEVAR of the ascending aorta requires determination of anatomical indication and a surgical technique that significantly differs from TEVAR for acute type B aortic dissection. Entry is present in the ascending aorta for two-thirds of aortic dissection cases, 44) and it is therefore important to ensure adequate landing zone when performing entry closure of the ascending aorta by TEVAR; however, attention should also be paid to potential interference with the coronary artery, aortic valve, and brachiocephalic artery by the stent graft. It has been reported that when the landing zone on the peripheral side is insufficient, debranching of the brachiocephalic artery may be considered, but 32% of patients with acute type A aortic dissection present with anatomical conditions suitable for TEVAR of the ascending aorta. 45) There is a retrograde approach from the femoral artery and an antegrade approach from the apex (Fig. 8) , but the detail of the procedures such as delivery of the stent graft and rapid pacing are largely due to the technological progress of transcatheter aortic valve 
Results of TEVAR for acute type A aortic dissection
This situation appears to be due to the strict selection of indicated cases, but the success rates of TEVAR and the surgical mortality rates are favorable (97%-100% and 0%-6.7%, respectively). [46] [47] [48] The most serious postoperative complication of concern is cerebral infarction. The incidence of brain complications among all TEVAR cases is 3.5%-5.0% 49, 50) ; however, in TEVAR for acute type A aortic dissection, because it is necessary to perform a surgical procedure in the ascending aorta with the lesion, it may be a higher-risk procedure. In addition, attention should be paid to the onset of endoleak, aortic rupture, dissection progression, coronary artery occlusion, and aortic valve dysfunction. Currently, TEVAR for acute type A aortic dissection does not exceed open surgery and is merely regarded as a rescue procedure for high-risk cases. We hope that improved TEVAR devices and technological innovation in the future will lead to further improvement in treatment results of acute type A aortic dissection.
Conclusion
There has definitely been a change from the traditional approach of performing conservative treatment for acute type B aortic dissection and emergency open surgery for acute type A aortic dissection. It is important that surgeons involved in the treatment of modern aortic diseases accurately evaluate new information as it develops and appropriately select treatments based on accumulated evidence.
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